Pharmacokinetic Properties of 99mTc-PSMA: A New Radiopharmaceutical for SPECT Imaging of Prostate Cancer

Prostate-specific membrane antigen (PSMA), which is overexpressed in advanced prostate cancer, is a well-established target for the development of antitumor diagnostic and therapeutic radiopharmaceuticals. The aim of this work is the preclinical study of the pharmacokinetics of a new radiopharmaceutical ^99mTc-PSMA. Tumor uptake of ^99mTc-PSMA is 1.81–3.91%/g with a maximum uptake of 3.91 ± 0.35%/g at 3 h of post-injection. The highest uptake (up to 140.11%/g) of ^99mTc-PSMA throughout the study was observed in the kidneys. Tumor uptake of ^99mTc-PSMA was higher than in other organs and tissues, except the kidneys